Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Essential thrombocythaemia (ET), drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No treatment has been shown to prevent progression to myelofibrosis or leukaemia.
Very low-risk patients receive nothing and low-risk patients aspirin, but the evidence for aspirin in CALR-mutated low-risk disease is thin and bleeding may outweigh benefit.
Prefibrotic myelofibrosis is still often misdiagnosed as ET, and the two need different counselling.
Pregnancy management rests on small series; interferon is preferred but randomised data are lacking.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Merck starts the Shorespan-007 trial against hydroxyurea in high-risk ET.
Complete response within 1 year 46.
Ruxolitinib matched but did not beat best available therapy after hydroxyurea failure, though it eased symptoms.
Marrow histology now distinguishes true ET from early myelofibrosis, which carries a worse outlook.
Klampfl and Nangalia find CALR exon 9 mutations in most JAK2-negative ET and myelofibrosis.